205 related articles for article (PubMed ID: 28077802)
1. NMI promotes hepatocellular carcinoma progression via BDKRB2 and MAPK/ERK pathway.
Zhao J; Dong QZ; Zhong F; Cai LL; Qin ZY; Liu Y; Lin CZ; Qin LX; He FC
Oncotarget; 2017 Feb; 8(7):12174-12185. PubMed ID: 28077802
[TBL] [Abstract][Full Text] [Related]
2. ERK pathway activation contributes to the tumor-promoting effects of hepatic stellate cells in hepatocellular carcinoma.
Xie YX; Liao R; Pan L; Du CY
Immunol Lett; 2017 Aug; 188():116-123. PubMed ID: 28668554
[TBL] [Abstract][Full Text] [Related]
3. OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway.
Li H; Miao Q; Xu CW; Huang JH; Zhou YF; Wu MJ
J Korean Med Sci; 2016 Aug; 31(8):1215-23. PubMed ID: 27478331
[TBL] [Abstract][Full Text] [Related]
4. As a downstream target of the AKT pathway, NPTX1 inhibits proliferation and promotes apoptosis in hepatocellular carcinoma.
Zhao Y; Yu Y; Zhao W; You S; Feng M; Xie C; Chi X; Zhang Y; Wang X
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31113871
[TBL] [Abstract][Full Text] [Related]
5. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
[TBL] [Abstract][Full Text] [Related]
6. Involvement of protein kinase C beta-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion.
Guo K; Liu Y; Zhou H; Dai Z; Zhang J; Sun R; Chen J; Sun Q; Lu W; Kang X; Chen P
Cancer Sci; 2008 Mar; 99(3):486-96. PubMed ID: 18167130
[TBL] [Abstract][Full Text] [Related]
7. The clinicopathological significance of miR-149 and PARP-2 in hepatocellular carcinoma and their roles in chemo/radiotherapy.
Lin L; Zhang YD; Chen ZY; Chen Y; Ren CP
Tumour Biol; 2016 Sep; 37(9):12339-12346. PubMed ID: 27300349
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory microenvironment and expression of chemokines in hepatocellular carcinoma.
Han KQ; He XQ; Ma MY; Guo XD; Zhang XM; Chen J; Han H; Zhang WW; Zhu QG; Nian H; Ma LJ
World J Gastroenterol; 2015 Apr; 21(16):4864-74. PubMed ID: 25944999
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma.
Sheng SL; Liu JJ; Dai YH; Sun XG; Xiong XP; Huang G
FEBS J; 2012 Oct; 279(20):3898-910. PubMed ID: 22897481
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
11. Targeting ODC1 inhibits tumor growth through reduction of lipid metabolism in human hepatocellular carcinoma.
Choi Y; Oh ST; Won MA; Choi KM; Ko MJ; Seo D; Jeon TW; Baik IH; Ye SK; Park KU; Park IC; Jang BC; Seo JY; Lee YH
Biochem Biophys Res Commun; 2016 Sep; 478(4):1674-81. PubMed ID: 27592554
[TBL] [Abstract][Full Text] [Related]
12. RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway.
Wang S; Huang X; Li Y; Lao H; Zhang Y; Dong H; Xu W; Li JL; Li M
Hepatology; 2011 Jun; 53(6):1932-42. PubMed ID: 21391225
[TBL] [Abstract][Full Text] [Related]
13. NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
Lu WJ; Chua MS; Wei W; So SK
Oncotarget; 2015 Oct; 6(30):29847-59. PubMed ID: 26359353
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
15. The herbal compound Songyou Yin (SYY) inhibits hepatocellular carcinoma growth and improves survival in models of chronic fibrosis via paracrine inhibition of activated hepatic stellate cells.
Bu Y; Jia QA; Ren ZG; Xue TC; Zhang QB; Zhang KZ; Zhang QB; You Y; Tian H; Qin LX; Tang ZY
Oncotarget; 2015 Nov; 6(37):40068-80. PubMed ID: 26517671
[TBL] [Abstract][Full Text] [Related]
16. Homeobox B9 is overexpressed in hepatocellular carcinomas and promotes tumor cell proliferation both in vitro and in vivo.
Li F; Dong L; Xing R; Wang L; Luan F; Yao C; Ji X; Bai L
Biochem Biophys Res Commun; 2014 Feb; 444(2):241-7. PubMed ID: 24462859
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma.
Sun BS; Dong QZ; Ye QH; Sun HJ; Jia HL; Zhu XQ; Liu DY; Chen J; Xue Q; Zhou HJ; Ren N; Qin LX
Hepatology; 2008 Dec; 48(6):1834-42. PubMed ID: 18972404
[TBL] [Abstract][Full Text] [Related]
19. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
[TBL] [Abstract][Full Text] [Related]
20. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway.
Wang F; Ying HQ; He BS; Pan YQ; Deng QW; Sun HL; Chen J; Liu X; Wang SK
Oncotarget; 2015 Apr; 6(10):7899-917. PubMed ID: 25760077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
